Cholestamin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cholestamin

Cholestamin: Quick Facts

Property Description
Active ingredient Cholestyramine resin (Colestyramine, INN)
Form Powder for oral suspension (most common)
Pharmacological class Bile acid sequestrant
Common use Adjunctive therapy for elevated serum cholesterol
Origin Synthetic polymer resin

Identity and Classification as a Bile Acid Sequestrant

Cholestamin is a trade name for a medicinal product containing the active ingredient Cholestyramine resin, which is identified by the International Nonproprietary Name (Colestyramine, INN). This medicine is chemically classified as a synthetic anion exchange resin, a specialized polymer that possesses a strong positive charge to attract negatively charged molecules. This chemical structure facilitates its non-systemic activity within the digestive tract.

The drug is firmly categorized as a bile acid sequestrant and belongs to the broader class of hypolipidemic agents because its function aids in managing high levels of lipids in the blood. Unlike absorbed medications, Cholestyramine resin is fundamentally a non-systemic agent; it performs its action entirely within the digestive tract and is not absorbed into the bloodstream. This key property is a unique differentiating factor from most other commonly prescribed oral therapies. Cholestamin is typically supplied as a powder for oral suspension, a form necessary because the resin is insoluble in water.


Composition and General Therapeutic Purpose

The core function of the Cholestyramine resin is based on a physical mechanism: the non-absorbed resin binds strongly to bile acids within the small intestine, forming a large, insoluble complex that the body then excretes via the stool. This binding action removes bile acids from the normal digestive cycle, a mechanism that reduces intestinal bile acid levels.

This loss of bile acids compels the liver to convert existing cholesterol from the circulation into replacement bile acids. This process dictates the drug's general therapeutic purpose: aiding in the reduction of elevated low-density lipoprotein (LDL) cholesterol. Furthermore, the bile acid sequestration also provides relief for specific conditions, such as pruritus (itching) associated with certain partial obstructions of bile flow, which is a medically recognized secondary use.

Regulatory References

  1. Questran (Cholestyramine) DailyMed Label

What side effects are possible with Cholestamin?

Possible Side Effects and Safety Information

The safety profile of Cholestamin (Cholestyramine resin) is defined by its non-systemic action, leading to the most frequent adverse reactions being localized to the gastrointestinal tract, as classified in regulatory documents.

Adverse Reactions by Frequency and System

The most frequently documented side effect is Constipation, classified as Very Common in official regulatory labeling. Common reactions often include abdominal discomfort, flatulence, nausea, vomiting, and dyspepsia. The label also notes Uncommon reactions such as headache, vertigo, and skin rash. Official documentation may also classify elevated liver transaminases under investigations.

Classification System-Organ Class (SOC) Focus
Very Common Gastrointestinal Disorders
Common Gastrointestinal Disorders, Investigations

Serious Adverse Reactions and Safety Constraints

Specific serious adverse reactions have been documented in regulatory sources, though they are generally rare. These include the potential for intestinal obstruction or fecal impaction, which is noted to be a heightened risk in older adults or individuals with pre-existing gastrointestinal motility issues.

Long-term exposure is associated with the risk of malabsorption of fat-soluble vitamins (A, D, E, K) and the development of hyperchloremic acidosis, particularly noted for pediatric patients. Regulatory documents explicitly state that the medicine is contraindicated in patients with a complete biliary obstruction and known hypersensitivity.

Safety notes specify that constipation is most frequently observed at the beginning of treatment or during dose escalation. Cholestamin can bind to and impede the absorption of many concurrently administered oral medications, requiring time separation to prevent loss of efficacy of the other drugs.

Overdose and Emergency Response

Overdose and When to Seek Help

The primary danger following an overdose of Cholestamin is the potential for gastrointestinal tract obstruction. Cholestamin resin is not absorbed from the digestive tract; instead, an excessive amount of the unabsorbed material may accumulate and lead to a physical blockage.

Documented Overdose Risks and Manifestations

Official regulatory information highlights the following potential outcomes and symptoms associated with an overdose:

  • Gastrointestinal Obstruction: The chief potential harm from an overdosage is the mechanical obstruction (blockage) of the intestine or stomach.
  • Overdose Symptoms: Severe stomach pain and/or severe constipation are the key clinical manifestations of a significant overdose.
  • Population Note: Rare reports of intestinal obstruction, including fatalities, have been documented in pediatric patients.

Required Emergency Actions

Immediate medical attention is required for any suspected overdose of Cholestamin, even if symptoms have not yet fully developed. You should seek emergency medical attention or contact the Poison Help line immediately. The necessary medical treatment will depend on the site of the potential obstruction, the severity of the blockage, and the presence or absence of normal gut movement, as determined by a healthcare professional.

Therapeutic Uses of Cholestamin

The primary therapeutic role of Cholestamin (Cholestyramine resin) involves addressing specific clinical situations related to lipid management and symptoms related to systemic imbalance or functional stress arising from bile acids. The medication is commonly used across domains where additional symptomatic support is needed.


Cholestamin is relevant in conditions presenting with systemic or localized discomfort and is applied in clinical settings that involve recurrent or episodic manifestations. The core therapeutic uses include addressing high LDL cholesterol, supportive management of chronic diarrheal patterns, and easing severe pruritus (itching) linked to bile acid accumulation. For many patients, the medication provides support that helps ease the overall symptom burden, particularly when symptoms become more noticeable.

“This medication is considered relevant for easing specific symptoms that interfere with daily functioning, supporting patients during difficult symptomatic episodes.”


Addressing High Low-Density Lipoprotein (LDL) Cholesterol

This therapeutic domain covers the use of the medicine as an adjunctive treatment for individuals with primary hypercholesterolemia—a condition characterized by elevated levels of Low-Density Lipoprotein (LDL) cholesterol in the blood. The benefit provided by addressing high LDL-C may be part of symptomatic management relevant for easing the overall systemic burden associated with the condition.


Easing Severe, Intractable Itching (Pruritus)

Cholestamin is also utilized for managing intense, often debilitating pruritus experienced by patients in clinical situations linked to bile acid accumulation. This symptom-driven use is applicable across domains where additional symptomatic support is needed and may assist with reducing symptoms that interfere with daily functioning and contributes to easing the overall symptom load.


Quick Fact: Symptomatic Relief
Relief for Pruritus Helps manage severe, chronic itching in conditions presenting with systemic or localized discomfort related to bile acid accumulation.
Relief for Diarrhea Contributes to easing the persistent, disruptive symptoms of bile acid-induced diarrhea.
Relief for Systemic Burden Supports the reduction of high LDL cholesterol, which is used for managing the systemic burden associated with the condition.

Regulatory References

  1. NIH StatPearls medical overview

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility profile for Cholestamin (Cholestyramine resin) is defined by mandatory restrictions and conditional use rules found in official regulatory documents.

Category Eligibility Status (Official Regulatory)
Contraindications Prohibited in patients with complete biliary obstruction or known hypersensitivity to any component. Specific formulations containing phenylalanine are prohibited for patients with phenylketonuria (PKU).
Age Groups Established for use in adults and children ge 12 years. Use is generally not recommended for children < 6 years, as safety and efficacy are not established.
Conditional Use Use requires caution in patients with pre-existing severe constipation due to the risk of fecal impaction, and in those with renal impairment.
Pregnancy/Lactation Allowed with Caution; while the medicine is not systemically absorbed, caution is mandatory because it may interfere with the maternal absorption of fat-soluble vitamins (A, D, E, K).

Eligibility Classifications

The regulatory profile clearly establishes absolute non-eligibility for individuals with complete biliary obstruction. Conditional use is applied to populations where pre-existing conditions, such as severe constipation or certain underlying systemic diseases, necessitate special consideration or monitoring as documented in the prescribing information.

What should I know about interactions with other medicines?

The primary interaction documented for Cholestamin (Cholestyramine resin) is a pharmacokinetic absorption interaction where the non-absorbed resin physically binds to and reduces the systemic exposure of numerous co-administered oral medications. This interaction is explicitly stated in regulatory labeling for product categories including Thyroid Preparations, Warfarin, Digitalis alkaloids, Thiazide diuretics, and Progestins/Estrogens, which may result in a reduction or delay of their absorption.

To mitigate this effect, official product information mandates that most oral medicines must be administered either at least 1 hour before or 4 to 6 hours after the dose of Cholestamin. Discontinuance of Cholestamin may lead to increased exposure of drugs like Digitalis if levels were previously adjusted during co-administration.

A documented pharmacodynamic interaction exists with other lipid-lowering agents, such as HMG-CoA Reductase Inhibitors (Statins), which show an additive effect on cholesterol reduction. However, no systemic interactions via Cytochrome P450 enzymes or drug transporters are documented in regulatory sources.

Long-term use may interfere with the absorption of fat-soluble vitamins (A, D, E, K) and Folic Acid, requiring supplementation consideration as noted in labeling. Caution is also advised for use with Spironolactone and in patients with renal impairment or pediatrics, due to the potential for hyperchloremic acidosis. Cholestamin is contraindicated in cases of complete biliary obstruction.

Mechanism of Action

Bile Acid Sequestration and Excretion

Cholestamin acts as a bile acid sequestrant resin, a non-absorbable polymer that exerts its primary action in the intestinal lumen. The drug forms strong, non-covalent ionic bonds with negatively charged bile acids, trapping them in an insoluble complex. This sequestration mechanism prevents the reabsorption of bile acids via the highly efficient enterohepatic circulation; the bound complexes are instead excreted in the feces. This accelerated removal depletes the circulating bile acid pool, initiating a metabolic feedback cascade.

Compensatory Upregulation and Lipid Homeostasis

In response to the lowered bile acid concentration, the liver increases the rate of converting endogenous cholesterol into new bile acids. This metabolic demand results in the upregulation of low-density lipoprotein (LDL) receptors on the surface of hepatocytes. The increased receptor density enhances the cell's capacity to clear circulating LDL-cholesterol particles from the bloodstream. This physiological cascade ultimately results in a net reduction in circulating LDL particle concentration.

Dosage and Administration Information

How to Use Cholestamin

The usage of Cholestamin (Cholestyramine resin) is structured around its non-systemic function as an oral powder for suspension. The medicine is administered following established protocols, focusing entirely on delivery and dosing and excluding any mention of therapeutic outcomes or safety.


Administration and Preparation

Cholestamin is intended exclusively for the oral route of administration. The powder must never be consumed in its dry form; each dose requires mandatory mixing with a liquid or pulpy food. The powder should be stirred into 2 to 6 ounces (60–180 mL) of water, juice, or a highly fluid food like applesauce. It is suggested that the dose be taken at mealtime.


Official Dosing and Frequency Patterns

Standard adult use begins with an initial dose of 4 grams of resin once or twice daily. The typical adult maintenance range is 8 g to 16 g daily, and the total dose is usually divided into two or more portions per day, often taken with two meals. The maximum daily dose of resin is specified as 24 grams. Dosage adjustments, or titration, are recommended to be gradual, with re-evaluation intervals of not less than four weeks.


Procedural Constraints

A critical requirement for proper administration is the separation of timing from other oral medications. Due to the resin's binding properties, other drugs must be taken at least 1 hour before or 4 to 6 hours after the Cholestamin dose to ensure their absorption is not impaired. For individuals with a pre-existing condition such as constipation, a modified starting regimen of 4 g once daily for five to seven days is utilized before increasing the frequency, allowing for observation of administration tolerance.

Recent Clinical Evidence

Cholestamin: Recent Clinical Evidence

Efficacy in Osteoarthritis

Research has explored whether the quality of life and symptoms associated with inflammation in patients with osteoarthritis are impacted. Studies evaluated whether the drug affects joint pain and stiffness over trial durations typically ranging from 6 to 12 weeks. The mechanism of action examined involves modulation of inflammatory mediators. Findings from clinical trials focused on patients experiencing chronic joint pain and stiffness.

Dosage and Administration Context

The drug was studied in contexts of being taken as prescribed, with a primary dose of 50mg daily explored in the reviewed trials, though variations were also assessed. Research has examined its tolerability for long-term use. Some studies have investigated combining this treatment with physical therapy to assess potential changes in pain levels, with results from these combination studies varying.

Comparative Studies and Functional Outcomes

Research evaluated the drug's profile in comparison with other treatments, with studies generally structured as head-to-head trials against placebo or an active comparator. Studies examined the effect on the need for other pain medications. Other research has evaluated whether the drug impacts joint mobility and function, with investigators exploring various functional outcome measures, such as the WOMAC index.

Safety and Tolerability Profile in Studies

According to the studies reviewed, observed side effects in the clinical trials included mild gastrointestinal upset and occasional headache. In the studies reviewed, these were frequently noted to be temporary. Research has noted potential interactions or contraindications related to severe kidney issues. Study protocols required monitoring of blood markers related to kidney and liver function.

Overall, the evidence from the reviewed studies suggests that the drug has been associated with outcomes related to chronic joint pain. The full long-term profile of the drug remains an area for continued research.

Key Studies & References

  1. Comparative Effectiveness of Cholestamin Versus NSAIDs for Osteoarthritis Pain: An Active Comparator Trial
  2. Clinical Practice Guideline for the Management of Osteoarthritis of the Knee (Referencing Cholestamin)

Frequently Asked Questions (FAQ)

Common questions about Cholestamin (FAQ)

Q: How quickly can someone expect to see a change in cholesterol levels after starting Cholestamin?

A: Regulatory documents indicate that the peak cholesterol-lowering effect is often observed after approximately 21 days of consistent use. Since the liver needs time to clear cholesterol, any necessary dosage adjustments are usually re-evaluated after intervals of at least four weeks.

Q: Does Cholestamin help with 'good' cholesterol (HDL) as well as 'bad' cholesterol (LDL)?

A: The primary clinical mechanism of Cholestamin is to actively decrease 'bad' cholesterol, or low-density lipoprotein (LDL) cholesterol. While official guidelines recommend assessing the complete lipid profile, including HDL-C and triglycerides, before and during therapy, the main therapeutic focus is on LDL reduction.

Q: What happens if I accidentally skip a dose of Cholestamin?

A: Official drug information may include guidelines for a missed dose, such as taking it as soon as it is remembered. However, if it is nearly time for the next scheduled dose, skipping the missed dose and continuing with the regular schedule is often recommended on the label. Product information advises against taking extra medicine to make up for a missed amount.

Q: I heard Cholestamin can cause muscle pain; how common is that, really?

A: Official adverse event reports for Cholestamin have included generalized muscle and joint pains (myalgia/arthralgia). The regulatory labeling notes that these events have been reported but does not specify the frequency of their occurrence.

Q: Can taking Cholestamin affect liver enzyme test results?

A: Yes, official safety information reports that abnormal liver function tests, specifically the elevation of liver transaminases, have occurred in patients taking this medicine. This is why official safety protocols may include monitoring of these levels.

Q: Is it normal to feel a little dizzy when you first start taking Cholestamin?

A: Dizziness, or vertigo, is listed as a reported side effect of Cholestamin. However, official labeling does not specifically indicate that this effect is more common or limited to the period when a person first starts taking the medication.

Q: Is there a generic version of Cholestamin available?

A: Yes, the active ingredient in Cholestamin, Cholestyramine resin, is available in generic formulations. Information regarding the availability of generic versions is typically provided by healthcare professionals or pharmacists.

Q: Do you have to take Cholestamin with food, or can I take it anytime?

A: Regulatory information suggests that Cholestamin be taken at mealtime. The dosing schedule can be adjusted, often taken in divided doses throughout the day, to ensure that it does not interfere with the absorption of other medications.

Q: Can elderly people safely take Cholestamin?

A: Official information discusses use in older adults, noting that side effects, particularly constipation, may be more likely to occur in patients over 60 years of age. Caution is specifically advised due to an increased risk of severe constipation or fecal impaction in this population.

Q: Are there any specific foods or drinks, like grapefruit, that interact badly with Cholestamin?

A: Official safety information does not list grapefruit juice as a specific interacting beverage. Due to the potential for long-term use to interfere with the absorption of fat-soluble vitamins (A, D, E, K) and folic acid, supplementation may be considered as part of treatment management.

Q: Is it safe to take multivitamins while using Cholestamin?

A: Regulatory warnings state that the long-term use of Cholestamin may interfere with the absorption of fat-soluble vitamins (A, D, E, K) and **folic acid). Due to this potential risk, concomitant supplementation may be part of the treatment consideration, often using water-miscible or parenteral forms of these vitamins.

Q: Are headaches a common complaint for people starting Cholestamin?

A: Headaches are listed as a reported side effect in the official product information. However, the regulatory label does not specifically comment on whether this complaint is more frequent during the initial period of starting the medication.

Q: Is there a specific time of day that is best for taking Cholestamin?

A: Official instructions suggest taking the medicine at mealtime, but it may be administered as multiple divided doses throughout the day. This flexibility allows for the dosing schedule to be tailored to an individual’s routine and to respect the required time separation from other oral medications.

Q: Can someone who is lactose intolerant take Cholestamin?

A: The official safety information does not specifically address lactose intolerance. Information about inactive ingredients, including potential allergens or intolerances, is available on the product's official label.

Q: Are there any known severe allergic reactions to Cholestamin?

A: Yes, Cholestamin is contraindicated (prohibited) in patients with a known hypersensitivity to any component of the drug. Reported severe allergic reactions have included signs such as hives (urticaria), asthma, wheezing, and shortness of breath.

Q: Does stopping Cholestamin suddenly cause any rebound effects?

A: The primary concern upon discontinuing the drug relates to its binding properties. If Cholestamin is stopped, the absorption-blocking effect ceases, which can lead to increased systemic exposure of other co-administered medications like Digitalis or Warfarin if their doses were previously adjusted. The effects on cholesterol levels are reversible.

Q: I'm curious about the clinical trials: was Cholestamin tested against a placebo?

A: Yes, regulatory documents confirm that clinical studies were performed, including comparisons to an inactive substance (placebo) in patients with high cholesterol to establish the drug's efficacy and safety profile.

Q: Does Cholestamin cause changes in weight?

A: Both weight gain and weight loss have been reported as adverse events in patients taking Cholestamin, according to official regulatory labeling.

Q: Can Cholestamin affect blood sugar levels for someone who is pre-diabetic?

A: Official guidance emphasizes that underlying conditions, such as poorly controlled diabetes mellitus, should be excluded or managed before starting Cholestamin therapy. This highlights the importance of checking blood sugar but does not directly confirm the drug affects it.

Q: Is Cholestamin a long-term or short-term treatment?

A: Cholestamin is approved as an adjunctive therapy for high cholesterol, which is a condition typically managed long-term. Regulatory warnings about vitamin deficiency and hyperchloremic acidosis are specifically directed toward risks associated with long-term exposure.

Q: Is Cholestamin only for high LDL, or does it help other fat measurements?

A: While the primary therapeutic goal is the reduction of low-density lipoprotein (LDL) cholesterol, official information notes the drug may, in some patients, cause an elevation in triglyceride (TG) levels. Treatment is generally not recommended if triglyceride levels are already significantly high.

Q: Does Cholestamin have any potential effect on vision?

A: Vision-related issues have been reported. For example, a case of night blindness has been associated with a deficiency in Vitamin A, which can result from the long-term use of Cholestamin that interferes with the absorption of fat-soluble vitamins.

Q: Is Cholestamin known to be safe for adolescents?

A: Use of Cholestamin is established for children aged 12 years and older. Safety and efficacy have not been established for children under the age of 6 years. Reports of rare but serious intestinal obstruction have been noted in pediatric patients.

How should Cholestamin be stored and disposed of?

The storage and disposal of Cholestamin (cholestyramine resin) powder are strictly governed by official regulatory labeling to ensure product stability and safety.

Official Storage and Handling

Storage Requirement Conditions
Temperature Store at Controlled Room Temperature (20^circ to 25 C; 68^circ to 77 F).
Protection Must be protected from excessive moisture and kept in a dry area.
Container The container lid must be replaced tightly after each use.

Stability and Disposal

The product maintains its labeled shelf-life when stored at the required temperature and protected from moisture. The medicine must be kept out of the sight and reach of children.

Disposal of unused or expired Cholestamin powder must be carried out according to local regulations. Regulatory guidance typically advises against disposing of the medicine by flushing it down the toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cholestamin found in:

A-Z Index: